The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.
One of the biggest problem areas in the fight against AMR is the research and development of new antibiotics. The science is hard and there is a problem with the current system for allocating investments into the expensive R&D needed to tackle superbugs that are always evolving.
Antibiotics are not like other medicines, because companies are working to find new medicines that in some cases will sit on the shelf and only be used against specific bugs – which are constantly evolving.
It can take 10 – 12 years and over a billion pounds to develop a new medicine and requires deep expertise, and that means there’s a big question mark over how we fund the research into antibiotics over the long-term that may only be used rarely.
But the new plan from the Government is a big step forward and could have a big impact on the future of health and research by making it sustainable for companies to keep investing. With AMR one of the biggest global health threats we face, pharmaceutical companies are keen to start finding solutions to this issue as soon as possible.
Read more here.